Case-control study of debrisoquine 4-hydroxylase, N-acetyltransferase 2, and apolipoprotein E gene polymorphisms in Parkinson's disease

Demetrius M. Maraganore, Matthew J. Farrer, John A. Hardy, Shannon K. McDonnell, Daniel J. Schaid, Walter A. Rocca

Research output: Contribution to journalArticle

43 Scopus citations

Abstract

We investigated the association of Parkinson's disease (PD) with two genes encoding liver-detoxifying enzymes, debrisoquine 4-hydroxylase (CYP2D6) and N-acetyltransferase 2 (NAT2), and with one gene related to Alzheimer's disease, apolipoprotein E (APOE). In a sample of 139 unrelated PD cases and 113 control subjects, the NAT2 M3 allele was associated with PD (odds ratio = 7.9; 95% confidence interval = 1.7-36.3). Case-control analyses for CYP2D6, APOE, and NAT2 M1 or M2 did not show a significant association. However, the age at onset of PD was significantly earlier in cases with the APOE E2/E3 genotype than in cases with the E3/E3 genotype.

Original languageEnglish (US)
Pages (from-to)714-719
Number of pages6
JournalMovement Disorders
Volume15
Issue number4
DOIs
StatePublished - Aug 4 2000

Keywords

  • APOE
  • CYP2D6
  • Case-control study
  • NAT2
  • Parkinson's disease
  • Susceptibility genes

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Case-control study of debrisoquine 4-hydroxylase, N-acetyltransferase 2, and apolipoprotein E gene polymorphisms in Parkinson's disease'. Together they form a unique fingerprint.

  • Cite this